CR20110505A - Compuestos organicos y sus usos - Google Patents

Compuestos organicos y sus usos

Info

Publication number
CR20110505A
CR20110505A CR20110505A CR20110505A CR20110505A CR 20110505 A CR20110505 A CR 20110505A CR 20110505 A CR20110505 A CR 20110505A CR 20110505 A CR20110505 A CR 20110505A CR 20110505 A CR20110505 A CR 20110505A
Authority
CR
Costa Rica
Prior art keywords
organic compounds
hcv
mitigation
hepatitis
virus
Prior art date
Application number
CR20110505A
Other languages
English (en)
Inventor
Trixi Brandl
Prakash Raman
Pascal Rigollier
Mohindra Seepersaud
Oliver Simic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20110505A publication Critical patent/CR20110505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Abstract

La presente solicitud describe compuestos orgánicos de lafórmula ( I ) : los cuales son útiles para el tratamiento, la prevención y/o la mitigación de enfermedades humanas, en particular por el virus de hepatitis C (HCV)
CR20110505A 2009-04-10 2011-09-27 Compuestos organicos y sus usos CR20110505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16840809P 2009-04-10 2009-04-10
US18103809P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
CR20110505A true CR20110505A (es) 2011-10-28

Family

ID=42332382

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110505A CR20110505A (es) 2009-04-10 2011-09-27 Compuestos organicos y sus usos

Country Status (30)

Country Link
US (4) US8512690B2 (es)
EP (1) EP2417108B1 (es)
JP (1) JP5528537B2 (es)
KR (2) KR20140048342A (es)
CN (1) CN102388023B (es)
AR (1) AR076236A1 (es)
AU (1) AU2010233472B2 (es)
BR (1) BRPI1015308A2 (es)
CA (1) CA2758146C (es)
CL (1) CL2011002494A1 (es)
CO (1) CO6440597A2 (es)
CR (1) CR20110505A (es)
CU (1) CU24046B1 (es)
EA (1) EA021554B9 (es)
EC (1) ECSP11011389A (es)
ES (1) ES2603744T3 (es)
HN (1) HN2011002635A (es)
IL (1) IL215310A (es)
MA (1) MA33155B1 (es)
MX (1) MX340733B (es)
MY (1) MY153766A (es)
NZ (1) NZ595458A (es)
PE (1) PE20120557A1 (es)
SG (1) SG174474A1 (es)
TN (1) TN2011000482A1 (es)
TW (2) TW201321368A (es)
UA (1) UA106367C2 (es)
UY (1) UY32551A (es)
WO (1) WO2010116248A1 (es)
ZA (1) ZA201106787B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543840T3 (es) * 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
CN101557819A (zh) * 2006-10-12 2009-10-14 诺瓦提斯公司 修饰的环孢素的用途
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
BR112013008510A2 (pt) * 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
EA022606B1 (ru) * 2010-10-08 2016-01-29 Новартис Аг Соли и полиморфы сульфамидных ингибиторов ns3
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP3413922A1 (en) * 2016-02-08 2018-12-19 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
CN109069658B (zh) 2016-02-08 2022-10-14 西纳福克斯股份有限公司 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法
EP3413920A1 (en) 2016-02-08 2018-12-19 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
JP2021507906A (ja) 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
CN114469952B (zh) * 2022-03-02 2023-09-19 中南大学湘雅三医院 特拉匹韦在制备malt1抑制剂、抗malt1依赖性肿瘤的药物中的应用及抗肿瘤药物

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
DE3803225A1 (de) 1988-02-04 1989-08-17 Hoechst Ag Aminosaeureamide mit psychotroper wirkung, verfahren zu ihrer herstellung, sie enthaltende mittel und deren verwendung
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DK0527815T3 (da) 1990-04-06 2000-11-06 Genelabs Tech Inc Hepatitis C-virus-epitop
EP0484281B2 (en) 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
AU6247594A (en) 1993-02-24 1994-09-14 Jui H. Wang Compositions and methods of application of reactive antiviral polymers
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
DK0730470T3 (da) 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
PT778263E (pt) 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JP2000506010A (ja) 1996-02-29 2000-05-23 イミューソル インコーポレイテッド Ｃ型肝炎ウイルスリボザイム
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
CA2292558C (en) 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2000009531A2 (en) 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
IL145475A0 (en) 1999-03-19 2002-06-30 Vertex Pharma Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
AP2001002290A0 (en) 1999-04-07 2001-12-31 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies.
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
MXPA03000397A (es) 2000-07-13 2003-05-27 Sankyo Co Derivados de aminoalcohol.
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002018198A1 (en) 2000-08-28 2002-03-07 Roe Jae Ick Generator of two-wheeled vehicle and lighting system thereby
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
HUP0500456A3 (en) 2000-11-20 2012-05-02 Bristol Myers Squibb Co Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
MXPA03005219A (es) 2000-12-12 2003-09-25 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
KR20030081343A (ko) 2000-12-15 2003-10-17 파마셋, 리미티드 플라비비리다에 감염 치료용 항바이러스제
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10102928B4 (de) 2001-01-23 2004-03-04 Infineon Technologies Ag Viterbi-Decoder und Verfahren zur Decodierung
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
KR100718371B1 (ko) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
US6973322B2 (en) 2001-12-22 2005-12-06 International Business Machines Corporation Personal travel agent using push services
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
PE20030857A1 (es) 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR20060015742A (ko) 2003-06-04 2006-02-20 제네랩스 테크놀로지스, 인코포레이티드 Ｈｃｖ 감염의 치료를 위한 질소 함유 헤테로아릴 유도체
CN1805931B (zh) 2003-06-17 2010-06-23 先灵公司 制备(1r,2s,5s)-6,6-二甲基-3-氮杂双环[3,1,0]己烷-2-羧酸酯或其盐的方法和中间体
GB0316521D0 (en) 2003-07-15 2003-08-20 Corus Uk Ltd Improvements in or relating to damping of rail tracks
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
CA2536570A1 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
EA200600540A1 (ru) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2541634A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060120162A (ko) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Ｈｃｖ 치료용 배합물
AU2004298498B2 (en) 2003-12-11 2008-09-11 Schering Corporation Inhibitors of hepatitis C virus NS3/NS4a serine protease
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200536528A (en) 2004-02-27 2005-11-16 Schering Corp Novel inhibitors of hepatitis C virus NS3 protease
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
TWI314927B (en) 2004-02-27 2009-09-21 Schering Corporatio Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005085242A1 (en) 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
AU2004320625B2 (en) 2004-06-07 2009-08-27 Anadys Pharmaceuticals, Inc. 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
BRPI0511900A (pt) 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2399628C2 (ru) 2004-10-01 2010-09-20 Скайнексис, Инк. Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
CN102160891A (zh) 2004-10-01 2011-08-24 威特克斯医药股份有限公司 Hcv ns3-ns4a蛋白酶抑制
ES2357587T3 (es) 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
JP2008526980A (ja) 2005-01-14 2008-07-24 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染症を治療するためのインドール誘導体
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20060276404A1 (en) 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
AU2006275413B2 (en) 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
CA2648298A1 (en) 2006-04-11 2007-10-25 Novartis Ag Organic compounds and their uses
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
BRPI0710183A2 (pt) 2006-04-11 2011-08-09 Novartis Ag compostos orgánicos e seus usos
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses

Also Published As

Publication number Publication date
MA33155B1 (fr) 2012-03-01
SG174474A1 (en) 2011-10-28
US20130022572A1 (en) 2013-01-24
US20140357551A1 (en) 2014-12-04
TWI387591B (zh) 2013-03-01
PE20120557A1 (es) 2012-05-23
US9206232B2 (en) 2015-12-08
US20130034519A1 (en) 2013-02-07
MY153766A (en) 2015-03-13
CO6440597A2 (es) 2012-05-15
AU2010233472A1 (en) 2011-10-20
KR20120004521A (ko) 2012-01-12
CL2011002494A1 (es) 2012-02-24
AU2010233472B2 (en) 2013-08-15
UA106367C2 (uk) 2014-08-26
CU24046B1 (es) 2014-12-26
EA201101477A1 (ru) 2012-05-30
EP2417108B1 (en) 2016-08-17
TW201321368A (zh) 2013-06-01
MX340733B (es) 2016-07-22
BRPI1015308A2 (pt) 2020-12-01
ECSP11011389A (es) 2011-11-30
CN102388023A (zh) 2012-03-21
NZ595458A (en) 2013-08-30
IL215310A (en) 2015-03-31
TW201040157A (en) 2010-11-16
MX2011010655A (es) 2011-10-21
HN2011002635A (es) 2014-08-25
IL215310A0 (en) 2011-12-29
US8512690B2 (en) 2013-08-20
EA021554B1 (ru) 2015-07-30
UY32551A (es) 2010-11-30
CA2758146A1 (en) 2010-10-14
KR101412309B1 (ko) 2014-06-27
CN102388023B (zh) 2014-05-28
AR076236A1 (es) 2011-05-26
ZA201106787B (en) 2012-08-28
KR20140048342A (ko) 2014-04-23
WO2010116248A1 (en) 2010-10-14
ES2603744T3 (es) 2017-03-01
EP2417108A1 (en) 2012-02-15
US8840878B2 (en) 2014-09-23
JP2012523404A (ja) 2012-10-04
US20100260709A1 (en) 2010-10-14
JP5528537B2 (ja) 2014-06-25
EA021554B9 (ru) 2018-06-29
TN2011000482A1 (en) 2013-03-27
US8613914B2 (en) 2013-12-24
CU20110191A7 (es) 2012-04-15
CA2758146C (en) 2017-06-06

Similar Documents

Publication Publication Date Title
CR20110505A (es) Compuestos organicos y sus usos
ECSP14013312A (es) Composiciones para el tratamiento de vhc
ECSP17084267A (es) Pirazolo[1,5—a]pirimidinas como agentes antivirales
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
CR11310A (es) Espiro-Pirrolidinas y su uso contra infeccion por el virus de Hepatitis C (HCV) y por el virus de Inmunodeficiencia Humana (VIH)
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
UY32325A (es) Inhibidores de ns3 proteasa del vhc
ECSP088518A (es) Nucleósidos antivirales
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY32457A (es) Vacuna del virus del dengue inactivado
UY34066A (es) Inhibidores del virus de la hepatitis c
CR20140078A (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
UY31849A (es) Nuevos compuestos como inhibidores de pde4
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
CO6771450A2 (es) Ureas asimétricas y usos médicos de las mismas
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
BR112014013972A8 (pt) inibidores de hcv nssa
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
ECSP13013075A (es) Método de tratamiento de la fiebre dengue